Immunocore gets FDA approval for cell therapy targeting melanoma

Kimmtrak is the first T cell receptor therapeutic, and first treatment for metastatic uveal melanoma, approved by the federal agency. Immunocore, a British biotech firm, has U.S. operations in Conshohocken.

Leave a Reply